AIM ImmunoTech Inc.AIMEarnings & Financial Report
AIM ImmunoTech Inc., formerly known as Hemispherx Biopharma Inc., is a biopharmaceutical company based in Ocala, Florida that is focused on the research and development of therapeutics to treat multiple types of cancers, various viruses and immune-deficiency disorders. Founded in 1990, the company has twenty-three employees.
AIM Q4 FY2025 Key Financial Metrics
Revenue
$21.0K
Gross Profit
N/A
Operating Profit
$-3.0M
Net Profit
$-4.2M
Gross Margin
N/A
Operating Margin
-14057.1%
Net Margin
-19881.0%
YoY Growth
-53.3%
EPS
$-6.46
AIM ImmunoTech Inc. Q4 FY2025 Financial Summary
AIM ImmunoTech Inc. reported revenue of $21.0K (down 53.3% YoY) for Q4 FY2025, with a net profit of $-4.2M (up 30.0% YoY) (-19881.0% margin).
Key Financial Metrics
| Total Revenue | $21.0K |
|---|---|
| Net Profit | $-4.2M |
| Gross Margin | N/A |
| Operating Margin | -14057.1% |
| Report Period | Q4 FY2025 |
AIM ImmunoTech Inc. Annual Revenue by Year
AIM ImmunoTech Inc. annual revenue history includes year-by-year totals (for example, 2025 revenue was $88.0K).
AIM ImmunoTech Inc. Quarterly Revenue & Net Profit History
AIM ImmunoTech Inc. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $21.0K | -53.3% | $-4.2M | -19881.0% |
| Q3 FY2025 | $26.0K | -25.7% | $-3.3M | -12630.8% |
| Q2 FY2025 | $25.0K | -50.0% | $-2.8M | -11176.0% |
| Q1 FY2025 | $16.0K | -60.0% | $-3.7M | -23156.3% |
| Q4 FY2024 | $45.0K | -30.8% | $-6.0M | -13260.0% |
| Q3 FY2024 | $35.0K | -23.9% | $-3.7M | -10571.4% |
| Q2 FY2024 | $50.0K | +19.0% | $-1.8M | -3672.0% |
| Q1 FY2024 | $40.0K | -18.4% | $-5.8M | -14542.5% |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $40000 | $50000 | $35000 | $45000 | $16000 | $25000 | $26000 | $21000 |
| YoY Growth | -18.4% | 19.0% | -23.9% | -30.8% | -60.0% | -50.0% | -25.7% | -53.3% |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $16.2M | $15.7M | $13.6M | $8.6M | $6.2M | $4.1M | $5.5M | $5.8M |
| Liabilities | $11.4M | $9.6M | $10.7M | $9.9M | $10.1M | $10.7M | $11.6M | $15.6M |
| Equity | $4.8M | $6.1M | $2.9M | $-1.3M | $-3.9M | $-6.5M | $-6.1M | $-9.8M |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-4.8M | $-3.0M | $-3.1M | $-4.0M | $-2.4M | $-1.5M | $-5.1M | $-2.0M |